Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Polymyalgia Rheumatica Treatment Market size was over USD 209.9 million in 2024 and is estimated to reach USD 385.6 million by the end of 2037, expanding at a CAGR of 5.2% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of polymyalgia rheumatica treatment is assessed at USD 220.8 million.
Polymyalgia Rheumatica is a moderately familiar inflammatory disorder that mainly affects people aged more than 50 years. According to the February 2025 NLM article, the yearly occurrence of the disorder ranges between 58 and 96 per 100,000 population. In addition, it is the second-most-common autoimmune rheumatic illness after rheumatoid arthritis, especially among the white population, and is common among 50% of people suffering from giant cell arteritis (GCA). Besides, this disorder progresses over a period of time in a few individuals, whereas it occurs overnight in others, thereby enhancing the market demand globally.
Moreover, the development of the market is attributed to the availability of different drugs in the existing market. As per the October 2023 article published by NEJM, Sarilumab is one of the medications approved for patients with the disorder in place of corticosteroids. The average pricing strategy of the drug is USD 2,000 per injection, contributing to the market upliftment. Besides, medical care institutes ensure consultation with patients before undergoing which positively impacts the market. For instance, arthritisCARE in its 2025 article denoted that USD 520 is the initial fee for an appointment, which reduces to USD 260.6 after a rebate of USD 259.4, thus suitable for market expansion internationally.
Polymyalgia Rheumatica Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Rise of the geriatric population: The international shift towards the elderly population is one of the growth factors for the polymyalgia rheumatica treatment market. According to the February 2025 WHO report, there will be an increase in the number of people aged 60 years from 1.1 billion to 1.4 billion by 2030, especially in developing nations. With this increase, the polymyalgia rheumatica condition is also expected to increase, which will eventually enhance the patient pool globally. This will further result in a huge demand for therapy and treatment options, thus driving the market expansion.
- Innovation in treatment solutions: The aspect of continuous research and development for the latest and innovative treatment options is yet another factor for the evolution of the polymyalgia rheumatica treatment market globally. As per an article published by Oxford Academic in March 2025, initial doses of oral glucocorticoids is an effective treatment for the condition that can cater to relapses in 76% of medical cases that affect 85% of patients. Besides, targeted and biologic therapies are also gaining attention and are readily being adopted by patients to effectively manage their condition, thus amplifying the market.
Challenges
- Occurrence of side effects: The long-term and excessive utilization of treatments and medications to aid polymyalgia rheumatica results in the development of side effects, which eventually cause a restraint in the expansion of the polymyalgia rheumatica treatment market. A few side effects, including cardiovascular issues, diabetes, and loss of bone, severely deteriorate the overall health condition of patients. However, there is a requirement to identify alternative therapeutic options with safety procedures that can overcome this barrier.
- Limited diagnosis and awareness: There is restricted consciousness and knowledge about polymyalgia rheumatica among people from all nations, due to which the polymyalgia rheumatica treatment market has not achieved maximum traction internationally. Besides, not only patients, but also medical professionals are unaware of the condition, which is a major roadblock for the market upliftment. This results in delayed diagnosis and treatment procedures that can make patients suffer. Therefore, efforts should be undertaken to spread awareness about the condition and initiate market enhancement.
Polymyalgia Rheumatica Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.2% |
|
Base Year Market Size (2024) |
USD 209.9 million |
|
Forecast Year Market Size (2037) |
USD 385.6 million |
|
Regional Scope |
|
Polymyalgia Rheumatica Treatment Segmentation
Route of Administration (Oral, Parenteral)
Oral segment is projected to capture over 94.8% polymyalgia rheumatica treatment market share by 2037. The segment’s growth is attributed to the provision of long-term relief to patients while ensuring treatment control. As stated in the February 2021 NLM article, almost 60% of molecular drug products are commercially available and administered by the oral route. Besides, oral formulations account for approximately 90% of pharmaceutical formulations, which are suitable for human utilization. Additionally, 84% of the best products are administered orally at a worth USD 35.0 billion, thereby driving the segment’s upliftment.
Drug Class (Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Nonsteroidal Anti-Inflammatory Drugs (NSAIDS))
By 2037, corticosteroids segment is estimated to account for around 51.6% polymyalgia rheumatica treatment market share. This growth is fueled by the segment’s ability to excel in relieving pain and symptoms, thereby making it an appropriate treatment option. According to the May 2023 NLM article, corticosteroids produce both immunosuppressive as well as anti-inflammatory effects, along with carbohydrate and protein metabolic effects. The intake should be limited, but 90% of patients suffer from adverse effects after 60 days of consumption. Therefore, patients need to follow medical recommendations while consuming corticosteroids, which positively impacts the segment’s growth.
Our in-depth analysis of the global polymyalgia rheumatica treatment market includes the following segments:
|
Route of Administration |
|
|
Drug Class |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPolymyalgia Rheumatica Treatment Industry - Regional Synopsis
North America Market Analysis
North America polymyalgia rheumatica treatment market is estimated to account for revenue share of around 47.4% by 2037. The aspect of robust medical and health infrastructures, key market players, and progressive treatment solutions are a few factors responsible for the development of the market in the region. Also, the region is prone to the incidence of chronic disorders, based on which there is an increased availability of personalized treatment options, which is an efficient driving factor for the market.
The polymyalgia rheumatica treatment market in the U.S. is gaining more traction based on the existence of treatment options by rheumatica providers. As per the clinical study published by NLM in February 2024, 26,102 patients affected with PMR were evaluated, out of which 81.2% suffered from hypertension, 52.4% from congestive heart issues, 41.3% from hyperlipidemia, and 36.0% from ischemic heart conditions. To combat the overall condition along with these illnesses, there was the provision of glucocorticoids to 92.3% of patients and a steroid-sparing agent to 13.1%. Additionally, a follow-up was initiated wherein antirheumatic medications were recommended to 39.0%, thereby enhancing the market demand.
There is a huge opportunity for the polymyalgia rheumatica treatment market to expand in Canada, owing to the involvement of the government in initiating funding and promoting healthy and standard lifestyles. For instance, in February 2025, an initiative was undertaken by the Canada Institute of Health Research- the HCCI2 Initiative, wherein an investment of USD 13.5 million was provided. The purpose of this was to visualize beyond the existing research and bring together the regional inflammation research community to cooperatively influence the proficiency of numerous research pillars, disciplines, institutes, and partners, thus catering to the market upliftment in the country.
APAC Market Statistics
The Asia Pacific region in the polymyalgia rheumatica treatment market is poised to be the fastest-growing region during the forecast period. The region’s growth is fueled by the presence of long-term pain management, the emergence of advanced therapies, the availability of biologics as suitable and standard treatment options, and the intake of medicines to reduce side effects and combat relapses. In addition, organizations as well as administrative bodies play a pivotal role in making contributions and initiating approvals, especially in India and China, to make products available to patients, thereby developing a prolific opportunity for market expansion in the region.
The polymyalgia rheumatica treatment market in India is significantly growing due to the presence of alternative treatment options that include methotrexate and other biologic agents. Besides, organizations in the country are initiating developments to focus on anti-inflammation, which is an optimistic outlook for the market. For instance, in January 2023, Sun Pharmaceutical Industries Limited acquired three brands- Disperzyme, Disperzyme-CD, and Phlogam from Aksigen Hospital Care. These have been approved by the Drugs Controller General of India for post-operative inflammation among patients undergoing a trivial operation.
The polymyalgia rheumatica treatment market in China is gaining more exposure owing to the presence of medications to effectively manage pain and inflammation. In addition, the population of the country with the disorder received ample treatment and diagnosis recommendations from regional professionals. According to the March 2023 NLM article, a clinical study was conducted wherein 40% to 60% of patients had PMR symptoms, and GCA has the capability to develop the condition among 15% of the population. However, to combat this, the country has medical strategies to ensure patient prognosis, thereby driving market upliftment.
Companies Dominating the Polymyalgia Rheumatica Treatment Landscape
- AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- argenx S
- Regeneron Pharmaceuticals Inc.
- Sanofi
- GSK plc
- Merck & Co., Inc.
- Pfizer Inc.
- Centurion Healthcare Private Limited
- Hovione
- MODASA, Pharmaceuticals Pvt. Ltd.
- F. Hoffmann-La Roche Ltd.
- Sun Pharmaceutical Industries Limited
- Bristol Myers Squib
- Regeneron Pharmaceuticals, Inc.
The development of the polymyalgia rheumatica treatment market highly depends upon contributions made by organizations from across nations. The implementation of strategies such as mergers and acquisitions, investments, product capacities, and service expansion readily impacts the market in a positive way. For instance, in September 2023, Sparrow Pharmaceuticals made an expansion for its PROST Phase 2 clinical trial pertaining to SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort. Therefore, with continuous clinical trials of products, companies are deliberately contributing to the market upliftment internationally.
Here's the list of some key players:
In the News
- In December 2024, Bristol Myers Squibb notified the U.S. FDA approval of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for intravenous use, a combination product of nivolumab co-formulated with recombinant human hyaluronidase in most previously approved adult indications.
- In February 2023, Regeneron Pharmaceuticals, Inc. and Sanofi proclaimed that the U.S. FDA has approved Kevzara for the treatment of polymyalgia rheumatica in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
Author Credits: Radhika Pawar
- Report ID: 7556
- Published Date: Apr 25, 2025
- Report Format: PDF, PPT
